{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Extrapulmonary+Small+Cell+Cancer",
    "query": {
      "condition": "Extrapulmonary Small Cell Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 13,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Extrapulmonary+Small+Cell+Cancer&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T15:52:35.553Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05420636",
      "title": "Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small-cell Lung Cancer",
        "Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "Iadademstat",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fox Chase Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-12-21",
      "completion_date": "2025-07-23",
      "has_results": false,
      "last_update_posted_date": "2025-07-30",
      "last_synced_at": "2026-06-10T15:52:35.553Z",
      "location_count": 3,
      "location_summary": "Buffalo, New York • Philadelphia, Pennsylvania • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05420636"
    },
    {
      "nct_id": "NCT07328490",
      "title": "Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Extensive-Stage Small Cell Lung Cancer",
        "Extrapulmonary Neuroendocrine Carcinoma",
        "Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Tarlatamab",
          "type": "DRUG"
        },
        {
          "name": "Sacituzumab Govitecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 0,
      "start_date": "2026-04-25",
      "completion_date": "2026-04-25",
      "has_results": false,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-06-10T15:52:35.553Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07328490"
    },
    {
      "nct_id": "NCT07278479",
      "title": "Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Large Cell Neuroendocrine Carcinoma",
        "Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)",
        "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)",
        "Small Cell Lung Cancer (SCLC)",
        "Gastroenteropancreatic NEC (GEP NEC)",
        "NEC of the Bladder",
        "Other DLL3 Expressing epNEC"
      ],
      "interventions": [
        {
          "name": "[212Pb]Pb-MP0712",
          "type": "DRUG"
        },
        {
          "name": "[203Pb]Pb-MP0712",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Molecular Partners AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2026-05-18",
      "completion_date": "2032-09",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-06-10T15:52:35.553Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Glen Burnie, Maryland • Omaha, Nebraska + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Glen Burnie",
          "state": "Maryland"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Princeton",
          "state": "New Jersey"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07278479"
    },
    {
      "nct_id": "NCT05652686",
      "title": "A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer (SCLC)",
        "Large Cell Neuroendocrine Cancer (LCNEC)",
        "Neuroendocrine Prostate Cancer (NEPC)",
        "Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)",
        "Neuroendocrine Carcinomas (NEC)",
        "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)"
      ],
      "interventions": [
        {
          "name": "Peluntamig (PT217)",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin + Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel.",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Phanes Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 203,
      "start_date": "2023-09-05",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2025-09-23",
      "last_synced_at": "2026-06-10T15:52:35.553Z",
      "location_count": 12,
      "location_summary": "Duarte, California • Denver, Colorado • Baltimore, Maryland + 8 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05652686"
    },
    {
      "nct_id": "NCT02146170",
      "title": "Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Small Cell Lung Cancer",
        "Extrapulmonary Small Cell Cancer",
        "Pulmonary Neuroendocrine Tumors",
        "Thymic Epithelial Tumors"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2000,
      "start_date": "2014-05-28",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-08",
      "last_synced_at": "2026-06-10T15:52:35.553Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02146170"
    },
    {
      "nct_id": "NCT06503146",
      "title": "18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma",
        "Small Cell Lung Cancer or Extrapulmonary Neuroendocrine Cancer (EP-NEC)",
        "Mesothelioma",
        "Pheochromocytoma/Paraganglioma (PPGL)",
        "Pancreatic Ductal Adenocarcinoma",
        "Ovarian Cancer",
        "Hepatocellular Carcinoma",
        "Gastric Cancer",
        "Cholangiocarcinoma",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "[18F]FAPI-74",
          "type": "DRUG"
        },
        {
          "name": "[18F]FDG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 320,
      "start_date": "2025-09-09",
      "completion_date": "2030-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-06-10T15:52:35.553Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06503146"
    },
    {
      "nct_id": "NCT07488923",
      "title": "A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Cancer (SCLC )",
        "Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)",
        "Gastroenteropancreatic NEC (GEP NEC)",
        "Neuroendocrine Prostate Cancer (NEPC)"
      ],
      "interventions": [
        {
          "name": "ML261",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Moonlight Bio, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2026-05",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-06-10T15:52:35.553Z",
      "location_count": 3,
      "location_summary": "Hackensack, New Jersey • New York, New York • Nashville, Tennessee",
      "locations": [
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07488923"
    },
    {
      "nct_id": "NCT03896503",
      "title": "Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Extensive Stage Lung Small Cell Carcinoma",
        "Extrapulmonary Small Cell Neuroendocrine Carcinoma",
        "Limited Stage Lung Small Cell Carcinoma",
        "Platinum-Resistant Lung Small Cell Carcinoma",
        "Platinum-Sensitive Lung Small Cell Carcinoma",
        "Recurrent Lung Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Berzosertib",
          "type": "DRUG"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Topotecan Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2019-12-30",
      "completion_date": "2026-06-23",
      "has_results": true,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-06-10T15:52:35.553Z",
      "location_count": 33,
      "location_summary": "Los Angeles, California • Newport Beach, California • Sacramento, California + 26 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03896503"
    },
    {
      "nct_id": "NCT07080242",
      "title": "Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Small Cell Lung Cancer Metastatic or Locally Advanced",
        "Neuroendocrine Cancer",
        "Metastatic Neuroendocrine Prostate Cancer",
        "Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma",
        "Metastatic Advanced Merkel Cell Carcinoma",
        "Locally Advanced Large Cell Neuroendocrine Carcinoma of the Lung",
        "Locally Advanced Extrapulmonary Neuroendocrine Carcinoma",
        "Locally Advanced Neuroendocrine Prostate Cancer",
        "Locally Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine",
        "Locally Advanced Merkel Cell Carcinoma",
        "Metastatic Large Cell Neuroendocrine Carcinoma of the Lung"
      ],
      "interventions": [
        {
          "name": "BL-M14D1",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SystImmune Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2025-04-28",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-06-10T15:52:35.553Z",
      "location_count": 20,
      "location_summary": "Huntsville, Alabama • Los Angeles, California • San Francisco, California + 14 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07080242"
    },
    {
      "nct_id": "NCT04010357",
      "title": "Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Small-cell Lung Cancer",
        "Large Cell Neuroendocrine Carcinoma of the Lung",
        "Extrapulmonary Small Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Abemaciclib,",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2020-01-13",
      "completion_date": "2026-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-06-10T15:52:35.553Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04010357"
    }
  ]
}